A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS.

Registry ID

RLM-MD-04

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ALLERGAN INC

Start date

2018-10-08

Completion date

2020-09-18

Last update

2018-06-04

Conditions

• DIABETIC GASTROPARESIS

View on source registry